Why did many Black volunteers not meet amyloid threshold requirements for trials?

Question

Accepted Answer

Many Black Volunteers Excluded from Alzheimer's Drug Trials Due to Amyloid Threshold Discrepancies

A significant proportion of Black volunteers did not meet the amyloid threshold requirements for clinical trials of new Alzheimer's drugs, including Leqembi and donanemab. Eisai reported that 49% of Black volunteers failed to meet these criteria, a rate substantially higher than the 22% observed in white participants and 55% for Hispanic individuals. This disparity led to a stark under-representation of Black individuals in the Leqembi trial, where they constituted only 4.5% of US participants, despite the disease being more prevalent in this demographic.
Potential Biological and Diagnostic Factors

Researchers hypothesize that the dementia observed in Black patients may be driven by factors other than beta-amyloid, or that the disease manifests differently across diverse populations. There is also a possibility that the biomarkers used to detect amyloid may perform differently in Black and white patients. For instance, the APOE4 gene variant, which is linked to Alzheimer's risk, exhibits varying prevalence and impact across different ancestries. This genetic variation could influence the formation of amyloid deposits and contribute to the observed discrepancies in trial eligibility.
Complicating Health Conditions and Biomarker Performance

The higher prevalence of certain health conditions among Black Americans, such as obesity, hypertension, high cholesterol, type 2 diabetes, and sleep apnea, could increase the risk of vascular dementia and complicate the presentation of Alzheimer's disease. These co-existing conditions might influence the disease's manifestation or interact with diagnostic markers. Furthermore, some studies suggest that tests used to identify Alzheimer's-associated proteins, like amyloid, might not perform uniformly across different racial groups, potentially leading to misinterpretations or exclusions.
Socioeconomic and Environmental Influences

Socioeconomic factors, including systemic racism, inequities in healthcare access, disparities in access to healthy food, exposure to pollution, and the cumulative effects of chronic stress, are also considered potential contributors to health differences. These broader societal issues may influence the underlying biology and health outcomes of different populations, potentially affecting their susceptibility to Alzheimer's and how the disease presents, thereby impacting their eligibility for clinical trials focused on specific pathological markers.

Reading history

Hide →

This history is cleared when the page is closed.

Why did many Black volunteers not meet amyloid threshold requirements for trials?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends